Hans Bitter is Vice President, Data Sciences at bluebird bio, a pioneering gene therapy company headquartered in Cambridge, MA developing gene therapies for severe genetic diseases and cancer. His main focus has centered on investigating from a correlative and translational perspective bluebird’s CAR-T therapies, including idecabtagene vicleucel (bb2121) for multiple myeloma. Previously, Hans was Global Head of Bioinformatics Oncology at the Novartis Institutes of BioMedical Research, where he oversaw work across the oncology portfolio ranging from target identification (including Project Drive, a systematic interrogation of cancer dependencies across cancer subtypes) to translational biomarker research (including identification of biomarkers of response and resistance to the CD19-targeting CAR T, Kymriah). Prior to NIBR, he was Head of Bioinformatics for Virology and Immunology at Hoffman-LaRoche. Hans began his career at two San Francisco area start-ups and received his PhD from the University of California at Berkeley and his AB from Princeton University.